The Moscow Exchange has changed the ticker of Artgen Biotech (ex Institute of Human Stem Cells, HSCI). The issuer’s new ticker is ABIO.
The ticker was changed due to the renaming of the company. The ticker of Artgen Biotech’s shares will be changed on August 18, 2023.
HSCI changed its name to Artgen Biotech due to rebranding aimed at making the company’s activities, strategy, and values clearer to the public and a wider range of investors. The annual general meeting of shareholders of the company on June 29, 2023 decided to rename the company and to include independent directors in the Board of Directors to fulfill one of the conditions for listing the company’s shares as second-level securities.
On July 11, the company submitted an application to the Moscow Exchange to be listed in the second-level quotation list.
Today, Artgen Biotech is a biotechnology company whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, diagnostics, and prevention methods that provide new means to combat socially significant and orphan diseases that are more effective than the existing ones.
The group includes companies of different development stages, from seed to early growth and maturity, as well as companies forming a biotech development ecosystem within the group.
Artgen Biotech is a strategic investor in industries that improve the efficiency and quality of medical care. The Company is developing an internal ecosystem to accelerate biotech companies and commercialize their developments.
The company was founded in 2003. Since 2009, it has been an issuer at the Moscow Exchange Innovation and Investment Market.